Ultragenyx Pharmaceutical (RARE) Other Gross PP&E Adjustments (2016 - 2024)
Historic Other Gross PP&E Adjustments for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Q4 2024 value amounting to $378.4 million.
- Ultragenyx Pharmaceutical's Other Gross PP&E Adjustments rose 118.83% to $378.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $378.4 million, marking a year-over-year increase of 118.83%. This contributed to the annual value of $378.4 million for FY2024, which is 118.83% up from last year.
- As of Q4 2024, Ultragenyx Pharmaceutical's Other Gross PP&E Adjustments stood at $378.4 million, which was up 118.83% from $374.0 million recorded in Q4 2023.
- In the past 5 years, Ultragenyx Pharmaceutical's Other Gross PP&E Adjustments registered a high of $378.4 million during Q4 2024, and its lowest value of -$38.6 million during Q2 2021.
- Moreover, its 5-year median value for Other Gross PP&E Adjustments was -$28.8 million (2022), whereas its average is $52.4 million.
- Its Other Gross PP&E Adjustments has fluctuated over the past 5 years, first tumbled by 5560.72% in 2020, then skyrocketed by 12214.03% in 2021.
- Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Other Gross PP&E Adjustments stood at $70.4 million in 2020, then soared by 122.14% to $156.3 million in 2021, then soared by 90.05% to $297.1 million in 2022, then rose by 25.85% to $374.0 million in 2023, then increased by 1.19% to $378.4 million in 2024.
- Its Other Gross PP&E Adjustments stands at $378.4 million for Q4 2024, versus $374.0 million for Q4 2023 and -$26.4 million for Q3 2023.